Chronos Therapeutics Overview

  • Founded
  • 2009
Founded
  • Status
  • Private
  • Latest Deal Type
  • Corporate
  • Investors
  • 6

Chronos Therapeutics General Information

Description

Developer of therapeutic drugs intended to offer treatment for nervous system disorders. The company's services engage in research and development of drugs for age-related disease treatments, as well as focus on re-positioning drugs and screening, discovery and development of novel proprietary drug candidates, enabling healthcare professionals to offer advanced treatment to patients suffering from nervous disorders and ensure faster recovery for them.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • 26 Beaumont Street
  • Oxfordshire
  • Oxford OX1 2NP
  • England, United Kingdom
+44 01865 000000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Chronos Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Corporate 20-Jul-2016 000.00 Completed Generating Revenue
5. Early Stage VC 09-Dec-2013 000.00 000.00 000.00 Completed Startup
4. Grant 01-Aug-2013 00.00 00.00 Completed Startup
3. Early Stage VC 01-Oct-2012 00.000 00.00 000.00 Completed Startup
2. Early Stage VC 01-Sep-2010 $3.95M $5.98M 000.00 Completed Startup
1. Early Stage VC 01-Jul-2009 $2.04M $2.04M 000.00 Completed Startup
To view Chronos Therapeutics’s complete valuation and funding history, request access »

Chronos Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 3 0,000,000 00.000000 00.00 00.00 00.00 00.000
Ordinary 3 000,000 00.000000 00.00 00.00 00.00
Ordinary 2 0,000,000 00.000000 00.0 00.0 00.0 0.000
Ordinary 1 3,605,837 $0.000162 $1.14 $1.14 $1.14 8.73%
Ordinary 2,487,314 $0.000162 $0.81 $0.81 1x $0.81 6.02%
To view Chronos Therapeutics’s complete cap table history, request access »

Chronos Therapeutics Executive Team (11)

Name Title Board Seat Contact Info
Huw Jones Ph.D Chief Executive Officer & Executive Chairman
Peter Jenner Ph.D Chief Scientific Officer
Kevin Thompson Ph.D Director, Chronoscreen
Tanya Palmer Director, Clinical Development
Mark Donaldson Finance Director
You’re viewing 5 of 11 executive team members. Get the full list »

Chronos Therapeutics Board Members (10)

Name Representing Role Since
Alexandre Akoulitchev Ph.D Self Scientific Director & Board Member 000 0000
Anthony Bromovsky Self Board Member 000 0000
Christian Millar Self Board Member 000 0000
Christopher Towler Ph.D Oxford Spin-out Equity Management Board Member 000 0000
Huw Jones Ph.D Chronos Therapeutics Chief Executive Officer & Executive Chairman 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Chronos Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Shire Corporation Minority 000 0000 000000 0
Odey Asset Management Hedge Fund Minority 000 0000 000000 0
Odey Swan Fund Venture Capital Minority 000 0000 000000 0
UK Innovation Agency Government 000 0000 000000 0
Oxford Spin-out Equity Management Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Chronos Therapeutics Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 (0 000-00000 20-Jul-2016 000000000 00000 00 Buildings and Property 000 00000 00.0
To view Chronos Therapeutics’s complete investments history, request access »